John Gill has bought ALT on 2 days since Dec 2025

John M. Gill, age 73, is an independent Director at Altimmune, Inc. (NASDAQ: ALT), having served on the board since August 2004 (originally with PharmAthene prior to the 2017 merger).( He serves on the Audit Committee (designated as the financial expert) and the Nominating & Corporate Governance Committee, contributing his deep expertise in financial oversight, biopharma operations, and board governance.(

A Certified Public Accountant (CPA) with a B.A. in Accounting and Economics from Rutgers University, Gill also served in the U.S. Marine Corps.( His career highlights include co-founding TetraLogic Pharmaceuticals (2003–2013, as President, CEO, and Director), serving as President and CEO of PharmAthene, Inc. (2015–2017 until the Altimmune merger), and senior roles at 3-Dimensional Pharmaceuticals (EVP, COO, Director; acquired by Johnson & Johnson in 2003) and SmithKline Beecham/GlaxoSmithKline (R&D executive and finance positions).( Recently, on December 23, 2025, Gill purchased 12,500 shares of Altimmune stock at $4.10 per share, owning approximately 12,500 shares with an estimated net worth tied to these holdings of at least $48,250.(

Written by Perplexity from public sources.